<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34787443</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>4-Iminooxazolidin-2-One as a Bioisostere of Cyanohydrin Suppresses EV71 Proliferation by Targeting 3C<sup>pro</sup>.</ArticleTitle><Pagination><StartPage>e0102521</StartPage><MedlinePgn>e0102521</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01025-21</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/Spectrum.01025-21</ELocationID><Abstract><AbstractText>The fatal pathogen enterovirus 71 (EV71) is a major cause of hand-foot-and-mouth disease (HFMD), which leads to serious neurological syndromes. While there are no effective clinical agents available for EV71 treatment thus far, EV71 3C protease (3C<sup>pro</sup>), a cysteine protease encoded by the virus, has become a promising drug target for discovery of antiviral drugs, given that it plays a crucial role in virus proliferation and interferes with host cell function. Here, we report two inhibitors of EV71 3C<sup>pro</sup>, FOPMC and FIOMC, that were developed from previously reported cyanohydrin derivative (<i>R</i>)-1 by replacing the acyl cyanohydrin group with 4-iminooxazolidin-2-one. FOPMC and FIOMC have potent antiviral activity and dramatically improved metabolic stability. These two inhibitors demonstrated broad anti-EV effects on various cell lines and five epidemic viral strains. We further illuminated the binding models between 3C<sup>pro</sup> and FOPMC/FIOMC through molecular docking and molecular dynamics simulations. The substitution of an acyl cyanohydrin group with 4-iminooxazolidin-2-one does make FOPMC and FIOMC potent anti-EV71 drug candidates as universal nonclassical bioisosteres with a cyanohydrin moiety. <b>IMPORTANCE</b> EV71 is one of the most epidemic agents of HFMD. Thus far, there are no antiviral drugs available for clinical usage. The conserved EV71 3C<sup>pro</sup> plays pivotal roles in virus proliferation and defense host immunity, as well as having no homology in host cells, making it a most promising antiviral target. In this work, we identified that propyl- and isopropyl-substituted 4-iminooxazolidin-2-one moieties (FOPMC and FIOMC) effectively inhibited five epidemic viral strains in rhabdomyosarcoma (RD), HEK-293T, and VeroE6 cell lines. The inhibition mechanism was also illustrated with molecular docking and molecular dynamics (MD) simulations. The successful replacement of the labile cyanohydrin greatly improved the stability and pharmacokinetic properties of (<i>R</i>)-1, making 4-iminooxazolidin-2-one a nonclassical bioisosteric moiety of cyanohydrin. This discovery addressed a critical issue of the primitive structural scaffold of these promising anti-EV71 inhibitors and could lead to their development as broad-spectrum anti-EV agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Binghong</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Meijun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Sen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Texas A&amp;M University, College Station, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Si</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Luqing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Nankai University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3507-3969</Identifier><AffiliationInfo><Affiliation>School of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C430593">cyanohydrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723008">4-iminooxazolidin-2-one</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="Y">3C Viral Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3C protease</Keyword><Keyword MajorTopicYN="N">4-iminooxazolidin-2-one</Keyword><Keyword MajorTopicYN="N">EV71</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34787443</ArticleId><ArticleId IdType="pmc">PMC8597634</ArticleId><ArticleId IdType="doi">10.1128/Spectrum.01025-21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Z, Xia S, Wang X, Lan Q, Li P, Xu W, Wang Q, Lu L, Jiang S. 2020. Sodium copper chlorophyllin is highly effective against enterovirus (EV) A71 infection by blocking its entry into the host cell. ACS Infect Dis 6:882&#x2013;890. doi:10.1021/acsinfecdis.0c00096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00096</ArticleId><ArticleId IdType="pubmed">32233455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Jiang Z, Xiao G, Cheng S, Wen Y, Wan C. 2015. Circadian rhythm disruption was observed in hand, foot, and mouth disease patients. Medicine 94:e601. doi:10.1097/MD.0000000000000601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000000601</ArticleId><ArticleId IdType="pmc">PMC4602470</ArticleId><ArticleId IdType="pubmed">25761178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Qi Z, Wang J. 2020. The function and mechanism of enterovirus 71 (EV71) 3C protease. Curr Microbiol 77:1968&#x2013;1975. doi:10.1007/s00284-020-02082-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-020-02082-4</ArticleId><ArticleId IdType="pubmed">32556480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, Mo X, Pu D, Wang X, Altmeyer R. 2012. Seroepidemiology of enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 53:285&#x2013;289. doi:10.1016/j.jcv.2011.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.025</ArticleId><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Hu XY, Yu XF. 2019. Current understanding of human enterovirus D68. Viruses 11:490. doi:10.3390/v11060490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan YW, Ang MJY, Lau QY, Poulsen A, Ng FM, Then SW, Peng J, Hill J, Hong WJ, Chia CSB, Chu JJH. 2016. Antiviral activities of peptide-based covalent inhibitors of the enterovirus 71 3C protease. Sci Rep 6:33663. doi:10.1038/srep33663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33663</ArticleId><ArticleId IdType="pmc">PMC5028882</ArticleId><ArticleId IdType="pubmed">27645381</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. 1995. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 39:195&#x2013;205. doi:10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q, Carratala A, Shim H, Bachmann V, Jensen JD, Kohn T. 2017. Resistance of echovirus 11 to ClO2 is associated with enhanced host receptor use, altered entry routes, and high fitness. Environ Sci Technol 51:10746&#x2013;10755. doi:10.1021/acs.est.7b03288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.est.7b03288</ArticleId><ArticleId IdType="pmc">PMC5607461</ArticleId><ArticleId IdType="pubmed">28837336</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Xu M, Yin Z. 2013. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res 97:183&#x2013;194. doi:10.1016/j.antiviral.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ML, Hsu TA, Chen TC, Chang SC, Lee JC, Chen CC, Stollar V, Shih SR. 2002. The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology 293:386&#x2013;395. doi:10.1006/viro.2001.1310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.1310</ArticleId><ArticleId IdType="pubmed">11886259</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW, Ferre RA, Brown EL, Binford SL, Harr JEV, DeLisle DM, Worland ST. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem 41:2806&#x2013;2818. doi:10.1021/jm980068d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980068d</ArticleId><ArticleId IdType="pubmed">9667970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen LJ, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao JH, Kosa MB, Liu B, Batugo MR, Gleeson JPR, Wu ZP, Liu J, Meador JW, Ferre RA. 2003. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem 46:4572&#x2013;4585. doi:10.1021/jm030166l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030166l</ArticleId><ArticleId IdType="pubmed">14521419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C-J, Shie J-J, Fang J-M, Yen G-R, Hsu JTA, Liu H-G, Tseng S-N, Chang S-C, Lee C-Y, Shih S-R, Liang P-H. 2008. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem 16:7388&#x2013;7398. doi:10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. 2016. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res 131:61&#x2013;65. doi:10.1016/j.antiviral.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ, Zalman LS, Burns-Naas LA, Tran JQ. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 49:2267&#x2013;2275. doi:10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X-N, Song Z-G, Jiang T, Shi B-S, Hu Y-W, Yuan Z-H. 2010. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection. World J Gastroenterol 16:201&#x2013;209. doi:10.3748/wjg.v16.i2.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i2.201</ArticleId><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H-C, Wang H-C, Shih S-R, Teng IF, Tseng C-P, Hsu JTA. 2011. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 203:1784&#x2013;1790. doi:10.1093/infdis/jir174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir174</ArticleId><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, Zhang X, Chen L, Hu Y, Yuan Z. 2013. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 97:264&#x2013;269. doi:10.1016/j.antiviral.2012.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Cai Q, Chen C, Li N, Peng X, Cai Y, Yin K, Chen X, Wang X, Zhang R, Liu L, Chen S, Li J, Lin T. 2013. Structures of enterovirus 71 3C proteinase (strain E2004104-TW-CDC) and its complex with rupintrivir. Acta Crystallogr D Biol Crystallogr 69:866&#x2013;871. doi:10.1107/S0907444913002862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444913002862</ArticleId><ArticleId IdType="pubmed">23633597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang J, Wang M, Jin Q, Cui S. 2011. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 85:10021&#x2013;10030. doi:10.1128/JVI.05107-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao L, Zhai Y, Ma J, Nie Q, Li T, Yin Z, Sun Y, Shang L. 2017. Inhibition of enterovirus 71 replication by an &#x3b1;-hydroxy-nitrile derivative NK-1.9k. Antiviral Res 141:91&#x2013;100. doi:10.1016/j.antiviral.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.01.002</ArticleId><ArticleId IdType="pubmed">28063993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao L, Zhai Y, Yin Z, Sun Y, Shang L. 2017. Structure of the enterovirus 71 3C protease in complex with NK-1.8k and indications for the development of antienterovirus protease inhibitor. Antimicrob Agents Chemother 61:e00298-17. doi:10.1128/AAC.00298-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00298-17</ArticleId><ArticleId IdType="pmc">PMC5487676</ArticleId><ArticleId IdType="pubmed">28461310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C, Xi C, Hu K, Gao W, Cai X, Qin J, Lv S, Du C, Wei Y. 2018. Inhibition of enterovirus 71 replication and viral 3C protease by quercetin. Virol J 15:116. doi:10.1186/s12985-018-1023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-018-1023-6</ArticleId><ArticleId IdType="pmc">PMC6069798</ArticleId><ArticleId IdType="pubmed">30064445</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z, Ding Y, Ke Z, Cao L, Li N, Ding G, Wang Z, Xiao W. 2016. Luteoloside acts as 3C protease inhibitor of enterovirus 71 in vitro. PLoS One 11:e0148693. doi:10.1371/journal.pone.0148693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148693</ArticleId><ArticleId IdType="pmc">PMC4752227</ArticleId><ArticleId IdType="pubmed">26870944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-J, Chang Y-C, Hsiao N-W, Hsieh J-L, Wang C-Y, Kung S-H, Tsai F-J, Lan Y-C, Lin C-W. 2012. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Methods 182:93&#x2013;98. doi:10.1016/j.jviromet.2012.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.03.020</ArticleId><ArticleId IdType="pubmed">22465253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG. 2015. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347:71&#x2013;74. doi:10.1126/science.1261962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261962</ArticleId><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Zhao X, Cui Z, Wang M, Wang Y, Li L, Sun Q, Yang X, Zeng D, Liu Y, Sun Y, Lou Z, Shang L, Yin Z. 2015. Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease. J Med Chem 58:9414&#x2013;9420. doi:10.1021/acs.jmedchem.5b01013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01013</ArticleId><ArticleId IdType="pubmed">26571192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Shang C, Yang P, Li L, Zhai Y, Yin Z, Wang B, Shang L. 2018. 4-Iminooxazolidin-2-one as a bioisostere of the cyanohydrin moiety: inhibitors of enterovirus 71 3C protease. J Med Chem 61:10333&#x2013;10339. doi:10.1021/acs.jmedchem.8b01335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01335</ArticleId><ArticleId IdType="pubmed">30365311</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Tijsma A, Neyts J, Spyrou JAB, Ren J, Grimes JM, Puerstinger G, Leyssen P, Fry EE, Rao Z, Stuart DI. 2015. Structure elucidation of coxsackievirus A16 in complex with GPP3 informs a systematic review of highly potent capsid binders to enteroviruses. PLoS Pathog 11:e1005165. doi:10.1371/journal.ppat.1005165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005165</ArticleId><ArticleId IdType="pmc">PMC4613828</ArticleId><ArticleId IdType="pubmed">26485389</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X, Mao L, Wan Z, Xu R, Ma Y, Shen L, Jin X, Zhang C. 2019. High proportion of coxsackievirus B3 genotype A in hand, foot and mouth disease in Zhenjiang, China, 2011&#x2013;2016. Int J Infect Dis 87:1&#x2013;7. doi:10.1016/j.ijid.2019.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2019.07.012</ArticleId><ArticleId IdType="pubmed">31330324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima LM, Barreiro EJ. 2005. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 12:23&#x2013;49. doi:10.2174/0929867053363540.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867053363540</ArticleId><ArticleId IdType="pubmed">15638729</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen PH. 2001. The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 4:471&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11727312</ArticleId></ArticleIdList></Reference><Reference><Citation>McCurdy CR, Jones RM, Portoghese PS. 2000. Investigation of phenolic bioisosterism in opiates: 3-sulfonamido analogues of naltrexone and oxymorphone. Org Lett 2:819&#x2013;821. doi:10.1021/ol005561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ol005561</ArticleId><ArticleId IdType="pubmed">10754685</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Xu B, Ma Y, Shang L, Ye S, Wang Y. 2021. Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease. Antiviral Res 192:105102. doi:10.1016/j.antiviral.2021.105102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105102</ArticleId><ArticleId IdType="pubmed">34082057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan JS, Reed A, Chen F, Stewart CN. 2006. Statistical analysis of real-time PCR data. BMC Bioinformatics 7:85. doi:10.1186/1471-2105-7-85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-85</ArticleId><ArticleId IdType="pmc">PMC1395339</ArticleId><ArticleId IdType="pubmed">16504059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess B, Kutzner C, van der Spoel D, Lindahl E. 2008. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435&#x2013;447. doi:10.1021/ct700301q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct700301q</ArticleId><ArticleId IdType="pubmed">26620784</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. 2005. GROMACS: fast, flexible, and free. J Comput Chem 26:1701&#x2013;1718. doi:10.1002/jcc.20291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20291</ArticleId><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM, Karplus M. 2009. CHARMM: the biomolecular simulation program. J Comput Chem 30:1545&#x2013;1614. doi:10.1002/jcc.21287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21287</ArticleId><ArticleId IdType="pmc">PMC2810661</ArticleId><ArticleId IdType="pubmed">19444816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjelkmar P, Larsson P, Cuendet MA, Hess B, Lindahl E. 2010. Implementation of the CHARMM Force Field in GROMACS: analysis of protein stability effects from correction maps, virtual interaction sites, and water models. J Chem Theory Comput 6:459&#x2013;466. doi:10.1021/ct900549r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct900549r</ArticleId><ArticleId IdType="pubmed">26617301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R, Kumar R, Lynn A, Open Source Drug Discovery Consortium. 2014. g_mmpbsa&#x2014;a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951&#x2013;1962. doi:10.1021/ci500020m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci500020m</ArticleId><ArticleId IdType="pubmed">24850022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>